Teva Pharmaceutical Industries Limited (TEVA) — Stock Price, Chart & Analysis
Teva Pharmaceutical Industries Limited (TEVA) is a Healthcare stock currently trading at $100, up 0.00% on the day. It carries a market capitalization of $46.09B and a trailing P/E ratio of 66.98. Over the past 52 weeks, TEVA has traded between $18.21 and $40.79. Teva Pharmaceutical Industries Limited does not currently pay a regular dividend. View the live TEVA chart, technical opinion, analyst ratings, fundamentals and latest news below.
Teva Pharmaceutical Industries Limited (TEVA) key data
| Price | $100 |
| Change (today) | +0.00% |
| Previous close | $100 |
| Market cap | $46.09B |
| P/E ratio (TTM) | 66.98 |
| EPS (TTM) | $0.59 |
| 52-week high | $40.79 |
| 52-week low | $18.21 |
| Beta | 0.80 |
| Avg. volume | 5.30M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
Frequently asked questions about Teva Pharmaceutical Industries Limited (TEVA)
How much does one share of Teva Pharmaceutical Industries Limited cost?
As of the latest update, one share of Teva Pharmaceutical Industries Limited (TEVA) trades at $100 (+0.00% today).
What is Teva Pharmaceutical Industries Limited's market cap?
Teva Pharmaceutical Industries Limited has a market capitalization of approximately $46.09B.
What is Teva Pharmaceutical Industries Limited's P/E ratio?
Teva Pharmaceutical Industries Limited has a trailing price-to-earnings (P/E) ratio of 66.98.
What is Teva Pharmaceutical Industries Limited's earnings per share (EPS)?
Teva Pharmaceutical Industries Limited's trailing twelve-month EPS is $0.59.
Does Teva Pharmaceutical Industries Limited pay a dividend?
Teva Pharmaceutical Industries Limited does not currently pay a regular dividend.
What is Teva Pharmaceutical Industries Limited's 52-week trading range?
Over the past year, TEVA has traded between $18.21 and $40.79.
What is the analyst price target for Teva Pharmaceutical Industries Limited?
The mean analyst price target for Teva Pharmaceutical Industries Limited is $41.00. This is informational only and not investment advice.
Latest Teva Pharmaceutical Industries Limited (TEVA) news
- Teva Eyes New Growth Phase After Securing Investment-Grade RatingsNews · Sep 23, 2026
- Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth PipelineNews · Sep 22, 2026
- Teva Pharmaceutical Industries (TEVA), Why Is It Back In The Spotlight?News · Sep 21, 2026
- Medincell's Partner Teva Presented New Data on Investigational Olanzapine LAI and UZEDY® at Psych Congress 2026News · Sep 21, 2026
- Remepy Welcomes Pharma R&D Leader, Eran Harary, MD, as Chief Medical Officer, to Advance Hybrid Drug™ PipelineNews · Sep 16, 2026
- Teva Says Pivot to Growth Gains Steam as Branded Drugs, Biosimilars OutperformNews · Sep 15, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live TEVA dashboard…